Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
204 hedge funds and large institutions have $2.4B invested in Global Blood Therapeutics, Inc. in 2022 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 78 increasing their positions, 62 reducing their positions, and 30 closing their positions.
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
28% more capital invested
Capital invested by funds: $1.89B → $2.4B (+$519M)
26% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 62
3% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 30
0% less call options, than puts
Call options by funds: $13.9M | Put options by funds: $14M
1% less funds holding
Funds holding: 206 → 204 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$47.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22M |
| 3 |
Goldman Sachs
New York
|
+$17.8M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$14.9M |
| 5 |
PA
Perceptive Advisors
New York
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$42.7M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$25.2M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$11.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.7M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$4.07M |
GBT Hedge Fund Activity: Q1 2022 in Review
204 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q1 2022, worth a combined $2.4B — up 28% from $1.89B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new GBT positions and 30 closed out — a net gain of 1 holder — while 78 added to existing stakes and 62 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $47.1M. The largest seller was Capital World Investors, exiting entirely with an estimated $42.7M sold.
- 204 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q1 2022, down from 206 in Q4 2021.
- Funds reported $2.4B of Global Blood Therapeutics, Inc. stock for Q1 2022, up 28% quarter-over-quarter.
- 31 funds opened new Global Blood Therapeutics, Inc. positions in Q1 2022 and 30 closed out, a net change of +1 holder.
- The largest Global Blood Therapeutics, Inc. buyer in Q1 2022 was OrbiMed, an estimated $47.1M added.
- The largest Global Blood Therapeutics, Inc. seller in Q1 2022 was Capital World Investors, an estimated $42.7M sold.
Based on aggregated 13F filings for Q1 2022.